
Uncover the complex interconnected factors that drive the progressive and worsening vicious cycle of COPD.

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.
Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.

Join Drs. Nicola Hanania, Surya Bhatt, and Celeste Porsbjerg for a session exploring the burden of COPD in patients with type 2 inflammation and review key cytokine pathways and Phase 3 data on emerging biologic therapies.

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

The infographic provides information about the clinical characteristics used to classify moderate COPD exacerbations and the impact of these events on lung function, future risk, and mortality.

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.
This infographic illustrates the compounded burden of coexisting CRSwNP and asthma and explains how type 2 inflammation underlies both conditions and impacts clinical outcomes in patients.